ACACA and gastric cancer: 6-PGDH inhibition decreased the NADPH/NADP+ ratio, increased ROS, activated AMPK, decreased ACC1 activity, and reduced lipid synthesis (Figures 4 and 5), suggesting that 6-PGDH is an attractive therapeutic target for gastric cancer.